Vakaramoko Diaby

Budget Impact of Aripiprazole Once Every Two Months Long-Acting Injectable for Adult Patients with Bipolar-I Disorder in the US

In this study, a cost-offset analysis was conducted to evaluate the budget impact of introducing a new 2-monthly injectable formulation of aripiprazole in commercial health plans. In a hy...

Vakaramoko Diaby ;

10/26/2023

Budget Impact of Aripiprazole Once Every Two Months Long-Acting Injectable for Adult Patients with Schizophrenia in the US

A cost-offset analysis was conducted to evaluate the budget impact of introducing a new 2-monthly injectable formulation of aripiprazole in commercial health plans. In a hypothetical heal...

Vakaramoko Diaby ;

10/26/2023

Cost-Offset Analysis of Aripiprazole Once-Monthly Long-Acting Injectable in Patients With First-Episode or Early-Phase Schizophrenia

A cost-offset analysis of the long-acting injectable formulation of aripiprazole monohydrate to evaluate the direct medical costs associated with an increase in time to first hospitalizat...

Vakaramoko Diaby ;

10/26/2023